

B. 510(k) SUMMARY (as required by 21 CFR 807.92)

Targon FN System
July 15, 2010

DEC 21 2010

COMPANY: Aesculap Implant Systems, LLC
3773 Corporate Parkway
Center Valley, PA 18034
Establishment Registration Number: 2916714

CONTACT: Kathy A. Racosky
(610) 984-9291 (phone)
610-791-6882 (fax)

TRADE NAME: Targon FN System

COMMON NAME: Internal fracture fixation device

CLASSIFICATION NAME: Device, Fixation, Proximal Femoral, Implant (JDO)

REGULATION NUMBER: 888.3030

SUBSTANTIAL EQUIVALENCE

Aesculap Implant Systems, LLC, believes that the Targon FN System is substantially equivalent to the Synthes Titanium Limited Contact Dynamic Hip Screw Plate [TILC-DHS] (K953607).

DEVICE DESCRIPTION

The Aesculap Implant Systems Targon FN System consists of a single tapered plate and screws (cancellous and bicortical design) in various sizes. The plate in this system accepts 6.5 mm cancellous screws proximally and 4.5 mm bicortical screw distally. The Aesculap Implant Systems Targon FN System is manufactured from Titanium Alloy and will be provided sterile.

PURPOSE FOR PREMARKET NOTIFICATION

The purpose for this submission is to gain marketing clearance for the Aesculap Implant Systems Targon FN System.

INDICATIONS FOR USE

The Aesculap Implant Systems Targon FN System is intended to be used for splinting, stabilization and fixation of the proximal femur.

TECHNOLOGICAL CHARACTERISTICS(compared to Predicate(s))

The Aesculap Implant Systems Targon FN System is considered substantially equivalent to other legally marketed predicate systems. Biomechanical testing of the subject device was found to be similar in performance to previously cleared proximal femoral fixation systems with similar indications.

PERFORMANCE DATA

All required testing per "Draft Guidance for the Preparation of Premarket Notifications (510(k)s) Applications for Orthopedic Devices-The Basic Elements" were done where applicable.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

Aesculap Implant Systems, LLC
c/o Ms. Kathy A. Racosky
Regulatory Affairs Specialist
3773 Corporate Parkway
Center Valley, Pennsylvania 18034

DEC 21 2010

Re: K102057
Trade/Device Name: Targon FN System
Regulation Number: 21 CFR 888.3030
Regulation Name: Single/multiple component metallic bone fixation appliances and accessories
Regulatory Class: Class II
Product Code: KTT
Dated: December 14, 2010
Received: December 16, 2010

Dear Ms. Racosky:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must


Page 2 -- Ms. Kathy A. Racosky

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

Handwritten signature of Mark N. Melkerson in black ink, consisting of a stylized first name and a last name with a flourish.

Mark N. Melkerson
Director Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

